DENVER, Colo., Nov 1, 2023 (www.247marketnews.com)- Monopar Therapeutics Inc (NASDAQ: MNPR) stated, this morning, that it’s presenting data, from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting. Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/Camsirubicin/mnpr-201-001-clinical-trial.
Monopar Therapeutics is trading at $0.628, up $0.179 (+39.78%), on 6.57M premarket shares traded.
Its 52-week range is $0.395 to $4.88. Its next key resistance point is 69-cents and this morning’s premarket high of 74-cents; if it can break through those, on strong volume, during the regular session, it may run above 90-cents.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.